Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies, Hope For Subunit Vaccines
NEW DELHI (February 19, 2018) - Aeras today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents.
Aeras Highlights Commitment to Eradicating the World’s Leading Infectious Disease Killer at the 5th Global Forum on Tuberculosis
Aeras will highlight the progress being made in TB vaccine research at the 5th Global Forum on TB Vaccines in New Delhi, India, February 20-23, 2018. Presentations will include new data from Aeras’s advancing portfolio of TB vaccines, including data from four clinical-stage candidates. Keep reading for all presentation details.
Rockville, MD, October 13, 2016 – The number of deaths from tuberculosis (TB) is significantly higher than previously reported, according to the World Health Organization (WHO), which released updated figures in the annual update to its Global Tuberculosis Report today.
Rockville, MD, September 28, 2016 –Aeras has launched the AerasSHARE Biorepository, a new website to allow researchers from other organizations to access specimens and datasets that were collected by Aeras and its research partners in an effort to facilitate state-of-the-art TB vaccine related science and promote world-wide collaboration among TB vaccine researchers.
Rockville, MD, June 16, 2016 – The Sanofi Pasteur-Aeras Joint Steering Committee for the Phase 2 trial (C-040-404/TUB09) convened on 14 June 2016 to review and discuss the recommendations of the study’s independent Data Monitoring Committee (DMC).